Early lethality and neuronal proteinopathy in mice expressing cytoplasm-targeted FUS that lacks the RNA recognition motif

References

• Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416–38.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205–8.
   PubMed Web of Science ®Google Scholar
• Vance C, Rogelj B, Hortobagyi T, de Vos KJ, Nishimura AL, Sreedharan J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208–11.
   PubMed Web of Science ®Google Scholar
• Hewitt C, Kirby J, Highley JR, Hartley JA, Hibberd R, Hollinger HC, et al. Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol. 2010;67:455–61.
   PubMed Web of Science ®Google Scholar
• Munoz DG, Neumann M, Kusaka H, Yokota O, Ishihara K, Terada S, et al. FUS pathology in basophilic inclusion body disease. Acta Neuropathol. 2009;118:617–27.
   PubMed Web of Science ®Google Scholar
• Neumann M, Roeber S, Kretzschmar HA, Rademakers R, Baker M, Mackenzie IR. Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol. 2009;118:605–16.
   PubMed Web of Science ®Google Scholar
• Doi H, Koyano S, Suzuki Y, Nukina N, Kuroiwa Y. The RNA binding protein FUS/TLS is a common aggregate-interacting protein in polyglutamine diseases. Neurosci Res. 2010; 66:131–3.
   PubMed Web of Science ®Google Scholar
• Doi H, Okamura K, Bauer PO, Furukawa Y, Shimizu H, Kurosawa M, et al. RNA binding protein TLS is a major nuclear aggregate-interacting protein in Huntingtin exon 1 with expanded polyglutamine-expressing cells. J Biol Chem. 2008;283:6489–500.
   PubMed Web of Science ®Google Scholar
• Iko Y, Kodama TS, Kasai N, Oyama T, Morita EH, Muto T, et al. Domain architectures and characterization of an RNA binding protein, TLS. J Biol Chem. 2004;279:44834–40.
   PubMed Web of Science ®Google Scholar
• Lerga A, Hallier M, Delva L, Orvain C, Gallais I, Marie J, et al. Identification of an RNA binding specificity for the potential splicing factor TLS. J Biol Chem. 2001;276:6807–16.
   PubMed Web of Science ®Google Scholar
• Tan AY, Manley JL. TLS inhibits RNA polymerase III transcription. Mol Cell Biol. 2010;30:186–96.
   PubMed Web of Science ®Google Scholar
• Tan AY, Riley TR, Coady T, Bussemaker HJ, Manley JL. TLS/FUS (translocated in liposarcoma/fused in sarcoma) regulates target gene transcription via single-stranded DNA response elements. Proc Natl Acad Sci U S A. 2012; 109:6030–5.
   PubMed Web of Science ®Google Scholar
• Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, et al. Induced ncRNAs allosterically modify RNA binding proteins in cis to inhibit transcription. Nature. 2008;454: 126–30.
   PubMed Web of Science ®Google Scholar
• Schwartz JC, Ebmeier CC, Podell ER, Heimiller J, Taatjes DJ, Cech TR. FUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2. Genes Dev. 2012; 26:2690–5.
   PubMed Web of Science ®Google Scholar
• Ishigaki S, Masuda A, Fujioka Y, Iguchi Y, Katsuno M, Shibata A, et al. Position-dependent FUS-RNA interactions regulate alternative splicing events and transcriptions. Sci Rep. 2012;2:529.
   PubMed Web of Science ®Google Scholar
• Nakaya T, Alexiou P, Maragkakis M, Chang A, Mourelatos Z. FUS regulates genes coding for RNA binding proteins in neurons by binding to their highly conserved introns. RNA. 2013;19:498–509.
   PubMed Web of Science ®Google Scholar
• Orozco D, Tahirovic S, Rentzsch K, Schwenk BM, Haass C, Edbauer D. Loss of fused in sarcoma (FUS) promotes pathological tau splicing. EMBO Rep. 2012;13:759–64.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Liu S, Liu G, Ozturk A, Hicks GG. ALS associated FUS mutations result in compromised FUS alternative splicing and autoregulation. PLoS Genet. 2013;9:e1003895.
   PubMed Web of Science ®Google Scholar
• Zinszner H, Sok J, Immanuel D, Yin Y, Ron D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J Cell Sci. 1997;110:1741–50.
   PubMed Web of Science ®Google Scholar
• Fujii R, Takumi T. TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines. J Cell Sci. 2005;118:5755–65.
   PubMed Web of Science ®Google Scholar
• Kanai Y, Dohmae N, Hirokawa N. Kinesin transports RNA: isolation and characterization of an RNA-transporting granule. Neuron. 2004;43:513–25.
   PubMed Web of Science ®Google Scholar
• Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A, et al. ALS associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 2010;29:2841–57.
   PubMed Web of Science ®Google Scholar
• Dormann D, Madl T, Valori CF, Bentmann E, Tahirovic S, Abou-Ajram C, et al. Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J. 2012;31:4258–75.
   PubMed Web of Science ®Google Scholar
• Deng Q, Holler CJ, Taylor G, Hudson KF, Watkins W, Gearing M, et al. FUS is Phosphorylated by DNA-PK and Accumulates in the Cytoplasm after DNA Damage. J Neurosci. 2014;34:7802–13.
   PubMed Web of Science ®Google Scholar
• Shelkovnikova TA, Robinson HK, Southcombe JA, Ninkina N, Buchman VL. Multistep process of FUS aggregation in the cell cytoplasm involves RNA-dependent and RNA-independent mechanisms. Hum Mol Genet. 2014; 23:5211–26.
   PubMed Web of Science ®Google Scholar
• Anderson P, Kedersha N. Stress granules: the Tao of RNA triage. Trends Biochem Sci. 2008;33:141–50.
   PubMed Web of Science ®Google Scholar
• Shelkovnikova TA, Robinson H, Connor-Robson N, Buchman VL. Recruitment into stress granules prevents irreversible aggregation of FUS protein mislocalized to the cytoplasm. Cell Cycle. 2013;12:3194–202.
   PubMed Web of Science ®Google Scholar
• Shelkovnikova TA, Peters OM, Deykin AV, Connor-Robson N, Robinson H, Ustyugov AA, et al. Fused in Sarcoma (FUS) Protein Lacking Nuclear Localization Signal (NLS) and Major RNA Binding Motifs Triggers Proteinopathy and Severe Motor Phenotype in Transgenic Mice. J Biol Chem. 2013;288:25266–74.
   PubMed Web of Science ®Google Scholar
• Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci. 2012;15:1488–97.
   PubMed Web of Science ®Google Scholar
• Bentmann E, Neumann M, Tahirovic S, Rodde R, Dormann D, Haass C. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43). J Biol Chem. 2012;287:23079–92304.
   PubMed Web of Science ®Google Scholar
• Liu X, Niu C, Ren J, Zhang J, Xie X, Zhu H, et al. The RRM domain of human fused in sarcoma protein reveals a non-canonical nucleic acid binding site. Biochim Biophys Acta. 2013;1832:375–85.
   PubMed Web of Science ®Google Scholar
• Clery A, Blatter M, Allain FH. RNA recognition motifs: boring? Not quite. Curr Opin Struct Biol. 2008;18:290–8.
   PubMed Web of Science ®Google Scholar
• Liu X, Niu C, Ren J, Zhang J, Xie X, Zhu H, et al. The RRM domain of human fused in sarcoma protein reveals a non-canonical nucleic acid binding site. Biochim Biophys Acta. 2012;1832:375–85.
   PubMed Web of Science ®Google Scholar
• Luthi A, van der Putten H, Botteri FM, Mansuy IM, Meins M, Frey U, et al. Endogenous serine protease inhibitor modulates epileptic activity and hippocampal long-term potentiation. J Neurosci. 1997;17:4688–99.
   PubMed Web of Science ®Google Scholar
• Ninkina N, Peters O, Millership S, Salem H, van der Putten H, Buchman VL. Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein. Hum Mol Gen. 2009;18:1779–94.
   PubMed Web of Science ®Google Scholar
• Peters OM, Millership S, Shelkovnikova TA, Soto I, Keeling L, Hann A, et al. Selective pattern of motor system damage in gamma-synuclein transgenic mice mirrors the respective pathology in amyotrophic lateral sclerosis. Neurobiol Dis. 2012;48:124–31.
   PubMed Web of Science ®Google Scholar
• Shelkovnikova TA, Robinson HK, Troakes C, Ninkina N, Buchman VL. Compromised paraspeckle formation as a pathogenic factor in FUSopathies. Hum Mol Gen. 2014;23:2298–312.
   PubMed Web of Science ®Google Scholar
• Schmittgen TD, Livak KJ. Analysing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–8.
   PubMed Web of Science ®Google Scholar
• Blair IP, Williams KL, Warraich ST, Durnall JC, Thoeng AD, Manavis J, et al. FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry. 2010;81:639–45.
   PubMed Web of Science ®Google Scholar
• DePaul R, Abbs JH, Caligiuri M, Gracco VL, Brooks BR. Hypoglossal, trigeminal, and facial motor neuron involvement in amyotrophic lateral sclerosis. Neurology. 1988;38:281–3.
   PubMed Web of Science ®Google Scholar
• Huang C, Zhou H, Tong J, Chen H, Liu YJ, Wang D, et al. FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. PLoS Genet. 2011;7:e1002011.
   PubMed Web of Science ®Google Scholar
• Qiu H, Lee S, Shang Y, Wang WY, Au KF, Kamiya S, et al. ALS associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J Clin Invest. 2014;124:981–99.
   PubMed Web of Science ®Google Scholar
• Shelkovnikova TA. Modelling FUSopathies: focus on protein aggregation. Biochem Soc Trans. 2013;41:1613–7.
   PubMed Web of Science ®Google Scholar
• Colombrita C, Onesto E, Megiorni F, Pizzuti A, Baralle FE, Buratti E, et al. TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motor neuron-like cells. J Biol Chem. 2012;287:15635–47.
   PubMed Web of Science ®Google Scholar
• Mitchell JC, McGoldrick P, Vance C, Hortobagyi T, Sreedharan J, Rogelj B, et al. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta Neuropathol. 2013;125:273–88.
   PubMed Web of Science ®Google Scholar